SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 2, 2003
----------------------------------------------------------------
Generex Biotechnology Corporation
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-25169 82-049021
-------- --------- ---------
(State or other jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
33 Harbor Square, Suite 202, Toronto, Ontario Canada M5J 2G2
------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 416/364-2551
---------------------------------------------------------------
-------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 5. Other Events
On June 2, 2003, Generex Biotechnology Corporation issued a press release
announcing that the Company will no longer be listed on the Nasdaq National
Market because the Company is not in compliance with the requirements of NASD
Marketplace Rule 4450(a)(3) which requires an issuer to have a minimum of
$10,000,000 in stockholders' equity. A copy of the press release is attached
hereto as Exhibit 99.1 and incorporated herein by reference.
(c) Exhibits
Exhibit No. Description
----------- -----------
99.1 Press release dated June 3, 2003.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENEREX BIOTECHNOLOGY CORPORATION
Dated: June 5, 2003 By: Rose C. Perri
--------------------------
Rose C. Perri
Chief Operating Officer
(principal financial officer)
Exhibit Index
-------------
Exhibit No. Description
----------- -----------
99.1 Press release dated June 3, 2003